459 related articles for article (PubMed ID: 30496877)
1. A Quantitative Clinical Decision-Support Strategy Identifying Which Patients With Oropharyngeal Head and Neck Cancer May Benefit the Most From Proton Radiation Therapy.
Brodin NP; Kabarriti R; Pankuch M; Schechter CB; Gondi V; Kalnicki S; Guha C; Garg MK; Tomé WA
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):540-552. PubMed ID: 30496877
[TBL] [Abstract][Full Text] [Related]
2. Individualized quality of life benefit and cost-effectiveness estimates of proton therapy for patients with oropharyngeal cancer.
Brodin NP; Kabarriti R; Schechter CB; Pankuch M; Gondi V; Kalnicki S; Garg MK; Tomé WA
Radiat Oncol; 2021 Jan; 16(1):19. PubMed ID: 33478544
[TBL] [Abstract][Full Text] [Related]
3. A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer.
Rwigema JM; Langendijk JA; Paul van der Laan H; Lukens JN; Swisher-McClure SD; Lin A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):553-562. PubMed ID: 30625409
[TBL] [Abstract][Full Text] [Related]
4. Protons in head-and-neck cancer: bridging the gap of evidence.
Ramaekers BL; Grutters JP; Pijls-Johannesma M; Lambin P; Joore MA; Langendijk JA
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1282-8. PubMed ID: 23273998
[TBL] [Abstract][Full Text] [Related]
5. Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization.
Michiels S; Barragán AM; Souris K; Poels K; Crijns W; Lee JA; Sterpin E; Nuyts S; Haustermans K; Depuydt T
Radiother Oncol; 2018 Jul; 128(1):161-166. PubMed ID: 28951008
[TBL] [Abstract][Full Text] [Related]
6. The price of robustness; impact of worst-case optimization on organ-at-risk dose and complication probability in intensity-modulated proton therapy for oropharyngeal cancer patients.
van de Water S; van Dam I; Schaart DR; Al-Mamgani A; Heijmen BJ; Hoogeman MS
Radiother Oncol; 2016 Jul; 120(1):56-62. PubMed ID: 27178142
[TBL] [Abstract][Full Text] [Related]
7. Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients.
de Jong BA; Battinelli C; Free J; Wagenaar D; Engwall E; Janssens G; Langendijk JA; Korevaar EW; Both S
Med Phys; 2023 Mar; 50(3):1305-1317. PubMed ID: 36373893
[TBL] [Abstract][Full Text] [Related]
8. NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy.
Jakobi A; Stützer K; Bandurska-Luque A; Löck S; Haase R; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
Acta Oncol; 2015; 54(9):1658-64. PubMed ID: 26340301
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome after pencil beam scanning proton therapy and dysphagia/xerostomia NTCP calculations of proton and photon radiotherapy delivered to patients with cancer of the major salivary glands.
Walser MA; Bachmann N; Kluckert J; Köthe A; Tully C; Leiser D; Lomax AJ; Bizzocchi N; Langendijk JA; Weber DC
Br J Radiol; 2023 Aug; 96(1148):20220672. PubMed ID: 37129312
[TBL] [Abstract][Full Text] [Related]
10. Impact of model and dose uncertainty on model-based selection of oropharyngeal cancer patients for proton therapy.
Bijman RG; Breedveld S; Arts T; Astreinidou E; de Jong MA; Granton PV; Petit SF; Hoogeman MS
Acta Oncol; 2017 Nov; 56(11):1444-1450. PubMed ID: 28828923
[TBL] [Abstract][Full Text] [Related]
11. Treatment planning comparison for head and neck cancer between photon, proton, and combined proton-photon therapy - From a fixed beam line to an arc.
Amstutz F; Krcek R; Bachtiary B; Weber DC; Lomax AJ; Unkelbach J; Zhang Y
Radiother Oncol; 2024 Jan; 190():109973. PubMed ID: 37913953
[TBL] [Abstract][Full Text] [Related]
12. Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort.
Blanchard P; Wong AJ; Gunn GB; Garden AS; Mohamed ASR; Rosenthal DI; Crutison J; Wu R; Zhang X; Zhu XR; Mohan R; Amin MV; Fuller CD; Frank SJ
Radiother Oncol; 2016 Dec; 121(3):381-386. PubMed ID: 27641784
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis.
Holliday EB; Kocak-Uzel E; Feng L; Thaker NG; Blanchard P; Rosenthal DI; Gunn GB; Garden AS; Frank SJ
Med Dosim; 2016; 41(3):189-94. PubMed ID: 27158021
[TBL] [Abstract][Full Text] [Related]
14. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
[TBL] [Abstract][Full Text] [Related]
15. Stricter Postoperative Oropharyngeal Cancer Radiation Therapy Normal Tissue Dose Constraints Are Feasible.
Su W; Wright CM; Lee DY; Kim M; Anstadt EJ; Teo BK; Carlson DJ; Lukens JN; Eisbruch A; Lin A
Pract Radiat Oncol; 2022; 12(4):e282-e285. PubMed ID: 35304348
[TBL] [Abstract][Full Text] [Related]
16. Optimal Allocation of Proton Therapy Slots in Combined Proton-Photon Radiation Therapy.
Loizeau N; Fabiano S; Papp D; Stützer K; Jakobi A; Bandurska-Luque A; Troost EGC; Richter C; Unkelbach J
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):196-207. PubMed ID: 33848609
[TBL] [Abstract][Full Text] [Related]
17. Proton therapy and oral mucositis in oral & oropharyngeal cancers: outcomes, dosimetric and NTCP benefit.
Nangia S; Gaikwad U; Noufal MP; Sawant M; Wakde M; Mathew A; Chilukuri S; Sharma D; Jalali R
Radiat Oncol; 2023 Jul; 18(1):121. PubMed ID: 37468950
[TBL] [Abstract][Full Text] [Related]
18. Patient selection for proton therapy using Normal Tissue Complication Probability with deep learning dose prediction for oropharyngeal cancer.
Huet-Dastarac M; Michiels S; Rivas ST; Ozan H; Sterpin E; Lee JA; Barragan-Montero A
Med Phys; 2023 Oct; 50(10):6201-6214. PubMed ID: 37140481
[TBL] [Abstract][Full Text] [Related]
19. Normal tissue complication probability modeling to guide individual treatment planning in pediatric cranial proton and photon radiotherapy.
Dell'Oro M; Wilson P; Short M; Hua CH; Merchant TE; Bezak E
Med Phys; 2022 Jan; 49(1):742-755. PubMed ID: 34796509
[TBL] [Abstract][Full Text] [Related]
20. Impact of setup and range uncertainties on TCP and NTCP following VMAT or IMPT of oropharyngeal cancer patients.
Hamming-Vrieze O; Depauw N; Craft DL; Chan AW; Rasch CRN; Verheij M; Sonke JJ; Kooy HM
Phys Med Biol; 2019 Apr; 64(9):095001. PubMed ID: 30921775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
